1. Purpose

This document outlines the guideline or procedure details for administration of magnesium sulphate for neuroprotection at the Women’s. This clinical guideline outlines the requirement for the use of Magnesium Sulphate to a woman at risk of preterm birth to prevent cerebral palsy in their child at the Women’s.

The neuroprotective role for antenatal magnesium sulphate therapy given to women at risk of preterm birth for the preterm fetus is now established. The number of women needed to be treated to benefit one baby by avoiding cerebral palsy is 63 (95% confidence interval 43 to 155). Given the beneficial effects of magnesium sulphate on substantial gross motor function in early childhood, outcomes later in childhood should be evaluated to determine the presence or absence of later potentially important neurological effects, particularly on motor or cognitive function.

2. Definitions

Cerebral palsy: Cerebral palsy is a term which includes a number of different diseases or condition that can arise any time during brain development. Approximately 45% of all cases of cerebral palsy are associated with preterm birth (Australian Cerebral Palsy Register Report December 2009) with the rate of cerebral palsy amongst neonatal survivors born at less than 28 weeks gestation up to 30 times higher compared with infants born at term.

3. Responsibilities

Staff caring for a woman at risk of preterm birth should be aware about this guideline.

4. Guideline

4.1 Recommendations for use

The use of MgSO₄ is recommended for neuroprotection of the fetus/infant/child:

- when women are at risk of imminent preterm birth before 30 weeks gestation
- when preterm birth before 30 weeks gestation is planned or definitely expected within 24 hours.

The use of MgSO₄ is recommended:

- regardless of the number of babies in utero
- regardless of the anticipated mode of birth
- whether or not antenatal corticosteroids have been given.

4.2 Dose

When birth is planned commence MgSO₄ as close to four hours before birth as possible.

Note: Ensure magnesium sulphate is administered concurrently via a Y-site with a compatible IV fluid.

Loading dose: using a 10ml vial of MgSO₄ prepare 4gram (i.e. 8ml) of magnesium sulphate 50% in a 10ml syringe, configure pump to accept the 10ml syringe and set the pump to 32mL an hour for 15 minutes.

Maintenance: once the loading dose has been completed, using the 50ml vial of magnesium sulphate, magnesium sulphate 50% in a 50ml syringe, re-set the pump to accept 50ml syringe and set the pump to administer the maintenance rate of 1g/hr (2mL/hour) or as ordered.

Continue the regime until birth or 24 hours, whichever comes first.

Urgent delivery: In situations where urgent delivery is necessary because of actual or imminent maternal or fetal compromise then delivery should not be delayed to administer MgSO₄.
Repeat doses: In the event that birth does not occur after giving MgSO₄ for neuroprotection of the infant, and preterm birth (less than 30 weeks gestation) again appears imminent (planned or definitely expected within 24 hours), a repeat dose of MgSO₄ may be considered.

4.3 Monitoring

Magnesium level monitoring

Measurement of magnesium levels will facilitate management where there are signs of toxicity or in the presence of renal impairment.

Serum magnesium concentrations should be checked every 6 hours in the antepartum and intrapartum phase (therapeutic level of magnesium: 1.7 to 3.5 mmol/L).

Magnesium is excreted by the kidneys and regular monitoring of serum levels should be conducted in women with oliguria (urine output <100mL over 4 hours) or urea >10mmol/L and those with renal impairment.

<table>
<thead>
<tr>
<th>Mg conc (mmol/L)</th>
<th>Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.8 - 1.0</td>
<td>Normal plasma level</td>
</tr>
<tr>
<td>1.7 - 3.5</td>
<td>Therapeutic range</td>
</tr>
<tr>
<td>2.5 - 5.0</td>
<td>ECG changes (P-Q interval prolongation, widen QRS complex)</td>
</tr>
<tr>
<td>4.0 – 5.0</td>
<td>Reduction in deep tendon reflexes</td>
</tr>
<tr>
<td>&gt; 5.0</td>
<td>Loss of deep tendon reflexes</td>
</tr>
<tr>
<td>&gt; 7.5</td>
<td>Sinoatrial and atrioventricular blockade. Respiratory paralysis and CNS depression</td>
</tr>
<tr>
<td>&gt; 12</td>
<td>Cardiac arrest</td>
</tr>
</tbody>
</table>

Note: If serum magnesium level is >3.5mmol/L, cease infusion and consult with obstetrician.

Clinical observations

During administration of the loading or bolus dose:

- 5 minutely blood pressure and pulse (x 4 readings)
- observe for the development of side effects
- check patellar reflexes after administration.

During administration of the maintenance infusion:

- ½ hourly blood pressure, pulse, and respiratory rate (pre-treatment respiratory rate should be ≥ 16 per minute). These may be undertaken hourly post-birth.
- 1 hourly patellar reflexes
- 1 hourly urine measures, 4 hourly testing of urinary protein
- 2 hourly temperature
- continuous electronic fetal monitoring from 26 weeks gestation until clinical review/discussion by medical staff. Between 24-26 weeks gestation, individualised management with regard to fetal monitoring will be considered
- maintain strict fluid balance chart.

Record patellar reflexes as:

- A = Absent
- N = Normal
Guideline

Magnesium Sulphate - Neuroprotection of Preterm Infants

- B = Brisk.

Request magnesium level and review management if:
- respiratory rate < 12 breaths/minute
- urine output < 100mLs in 4 hours
- loss of patellar reflexes
- further seizures occur.

Response to magnesium toxicity:
The following clinical signs of magnesium toxicity must be reviewed by a consultant obstetrician/anaesthetist:
- urine output <100mL in 4 hours
- absent patellar reflexes
- respiratory depression.

The antidote for magnesium toxicity is: 10mL calcium gluconate available as 2.2 mmol calcium in 10mL vial (formerly known as 10% solution) over 10 minutes by slow intravenous injection. The patient requires ECG monitoring during and after administration because of the potential for cardiac arrhythmias.

Resuscitation and ventilator support should be available during and after dose administration of both magnesium sulphate and calcium gluconate.

CEASE Magnesium infusion in the following emergencies:
- respiratory arrest: call: Code Blue - Adult and Child (intranet)

4.4 Potential interactions
There is a potential theoretical interaction between MgSO₄ and nifedipine resulting in hypotension and neuromuscular blockade effects. This is seldom reported in clinical practice (Snyder & Cardwell, 1989; Ben-Ami et al, 1994). If hypotension occurs, nifedipine and MgSO₄ administration should be ceased.

5. Evaluation, monitoring and reporting of compliance to this guideline
Compliance to this guideline will be monitored by review of incidents reported through VHIMS.

6. References
See Evidence Table over the page.
Guideline

Magnesium Sulphate - Neuroprotection of Preterm Infants

References


Evidence Table

<table>
<thead>
<tr>
<th>Author/s</th>
<th>Title</th>
<th>Source</th>
<th>Level of Evidence</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crowther CA, Hiller JE, Doyle LW, Haslam RR for the Australasian Collaborative Trial of Magnesium sulphate (ACTO MgSO₄) Collaborative Group.</td>
<td>Effect of magnesium sulphate given for neuroprotection before preterm birth a randomised controlled trial.</td>
<td>JAMA 2003;290:2669-2676.</td>
<td>II</td>
<td>RCT n =1,064</td>
</tr>
</tbody>
</table>
# Guideline

## Magnesium Sulphate - Neuroprotection of Preterm Infants

<table>
<thead>
<tr>
<th>Author/s</th>
<th>Title</th>
<th>Source</th>
<th>Level of Evidence</th>
<th>Comments</th>
</tr>
</thead>
</table>

### 7. Legislation/Regulations related to this guideline

Not applicable.
8. Appendices

Not applicable.

The policies, procedures and guidelines on this site contain a variety of copyright material. Some of this is the intellectual property of individuals (as named), some is owned by The Royal Women's Hospital itself. Some material is owned by others (clearly indicated) and yet other material is in the public domain.

Except for material which is unambiguously and unarguably in the public domain, only material owned by The Royal Women's Hospital and so indicated, may be copied, provided that textual and graphical content are not altered and that the source is acknowledged. The Royal Women's Hospital reserves the right to revoke that permission at any time. Permission is not given for any commercial use or sale of this material.

No other material anywhere on this website may be copied (except as legally allowed for under the Copyright Act 1968) or further disseminated without the express and written permission of the legal holder of that copyright.

Advice about requesting permission to use third party copyright material or anything to do with copyright can be obtained from General Counsel.